Literature DB >> 28611330

Mini review: Multifaceted role played by cyclin D1 in tumor behavior.

Reena Rachel John1, N Malathi2, C Ravindran3, Soumya Anandan2.   

Abstract

The objective of this paper is to discuss and put forward the various diversified roles of cyclin D1 in cancer. Neoplasia is defined by abnormal regulation of the cell cycle. Cyclin D1 could be a protein derived from the PRAD1, CCND1, or bcl-1 sequence on body 11q13 that is concerned in each traditional regulation of the cell cycle and pathologic process. Within the G1 (resting) part of the cell cycle, cyclin D1 in conjunction with its cyclin-dependent enzyme (cyclin-dependent kinase) partner is accountable for transition to the S (DNA synthesis) part by phosphorylating the merchandise of the metastatic tumor sequence (protein retinoblastoma) that then releases transcription factors vital within the initiation of DNA replication. Amplification of the sequence or overexpression of the cyclin D1 releases a cell from its traditional controls and causes transformation to a malignant composition. Analysis of those changes provides vital diagnostic information in oral carcinogenesis and is of prognostic value in several cancers. Data of cyclin D1's role in malignancy at the assorted sites provide a basis on which future treatment directed against this molecule will proceed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28611330     DOI: 10.4103/ijdr.IJDR_697_16

Source DB:  PubMed          Journal:  Indian J Dent Res        ISSN: 0970-9290


  20 in total

1.  Cyclin D1 Expression in Patients with Laryngeal Squamous Cell Carcinoma.

Authors:  Vahid Zand; Fariba Binesh; Mojtaba Meybodian; Farzan Safi Dahaj; Arezoo Alamdar Yazdi
Journal:  Iran J Pathol       Date:  2020-05-01

2.  Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.

Authors:  Jefferson da Rocha Tenório; Leorik Pereira da Silva; Marília Gabriela de Aguiar Xavier; Thalita Santana; George João Ferreira do Nascimento; Ana Paula Veras Sobral
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-12       Impact factor: 2.503

3.  CCND1 silencing suppresses liver cancer stem cell differentiation through inhibiting autophagy.

Authors:  Hongying Zhang
Journal:  Hum Cell       Date:  2019-10-30       Impact factor: 4.174

4.  HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway.

Authors:  Hao Huang; Yong Han; Xingjiu Yang; Mengyuan Li; Ruimin Zhu; Juanjuan Hu; Xiaowei Zhang; Rongfei Wei; Kejuan Li; Ran Gao
Journal:  Oncotarget       Date:  2017-10-17

5.  MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma.

Authors:  Chen Dai; Yan Zhang; Zhihua Xu; Mengxian Jin
Journal:  Cancer Cell Int       Date:  2020-03-30       Impact factor: 5.722

6.  LncRNA HOTAIRM1/HOXA1 Axis Promotes Cell Proliferation, Migration And Invasion In Endometrial Cancer.

Authors:  Xianli Li; Li Pang; Zhuo Yang; Jing Liu; Weishan Li; Danbo Wang
Journal:  Onco Targets Ther       Date:  2019-12-13       Impact factor: 4.147

7.  Inhibition Effect of Dictyophora Polysaccharides on Human Hepatocellular Carcinoma Cell Line HCC-LM3.

Authors:  Ting Hu; Kaiju Zhang; Di Pan; Xueli Pan; Hongyan Yang; Jiayan Xiao; Xiangchun Shen; Peng Luo
Journal:  Med Sci Monit       Date:  2020-05-06

8.  Converse Smith-Martin cell cycle kinetics by transformed B lymphocytes.

Authors:  K Pham; A Kan; L Whitehead; R J Hennessy; K Rogers; P D Hodgkin
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

9.  MicroRNA‑4712‑5p promotes proliferation of the vulvar squamous cell carcinoma cell line A431 by targeting PTEN through the AKT/cyclin D1 signaling pathways.

Authors:  Shaojie Yang; Yanyan Zhao; Lufang Wang; Chang Liu; Ye Lu; Zhidong Fang; Hongshuang Shi; Wenyi Zhang; Xin Wu
Journal:  Oncol Rep       Date:  2019-09-17       Impact factor: 3.906

10.  Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress.

Authors:  Annalisa Pecoraro; Pietro Carotenuto; Giulia Russo; Annapina Russo
Journal:  Sci Rep       Date:  2019-10-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.